PE20260136A1 - Composiciones farmaceuticas de glp1 - Google Patents
Composiciones farmaceuticas de glp1Info
- Publication number
- PE20260136A1 PE20260136A1 PE2025002371A PE2025002371A PE20260136A1 PE 20260136 A1 PE20260136 A1 PE 20260136A1 PE 2025002371 A PE2025002371 A PE 2025002371A PE 2025002371 A PE2025002371 A PE 2025002371A PE 20260136 A1 PE20260136 A1 PE 20260136A1
- Authority
- PE
- Peru
- Prior art keywords
- glp1
- pharmaceutical compositions
- fluoro
- composition
- oxomidazol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263340591P | 2022-05-11 | 2022-05-11 | |
| PCT/US2023/021637 WO2023220109A1 (en) | 2022-05-11 | 2023-05-10 | Glp1 pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20260136A1 true PE20260136A1 (es) | 2026-01-21 |
Family
ID=86732348
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2025002371A PE20260136A1 (es) | 2022-05-11 | 2023-05-10 | Composiciones farmaceuticas de glp1 |
| PE2024002463A PE20251285A1 (es) | 2022-05-11 | 2023-05-10 | Composiciones farmaceuticas de glp1 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2024002463A PE20251285A1 (es) | 2022-05-11 | 2023-05-10 | Composiciones farmaceuticas de glp1 |
Country Status (17)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20250009A1 (es) * | 2022-05-11 | 2025-01-07 | Lilly Co Eli | Composiciones de comprimidos de glp1 |
| EP4777197A2 (en) | 2023-09-14 | 2026-07-22 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| KR20260118441A (ko) * | 2023-11-21 | 2026-07-30 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 헤테로시클릭 화합물, 이의 제조 방법 및 의약에서 이의 응용 |
| WO2025109387A1 (en) | 2023-11-24 | 2025-05-30 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| TW202600132A (zh) | 2024-03-08 | 2026-01-01 | 美商安尼波那生物公司 | 用於治療肥胖症及提高減重之方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7115565B2 (en) * | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
| CA2434641A1 (en) * | 2001-01-18 | 2002-08-22 | Pharmacia And Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
| AU2007293032A1 (en) * | 2006-09-08 | 2008-03-13 | Merck Sharp & Dohme Corp. | Liquid pharmaceutical formulations for oral administration of a CGRP antagonist |
| JOP20190060A1 (ar) * | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
| JP7461104B2 (ja) * | 2017-11-29 | 2024-04-03 | 中外製薬株式会社 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 |
| PL3984523T3 (pl) * | 2018-12-07 | 2026-02-02 | Neurocrine Biosciences, Inc. | Antagonista receptora crf1, jego formulacje farmaceutyczne i postacie stałe do leczenia wrodzonego przerostu nadnerczy |
| US11884672B2 (en) * | 2019-05-14 | 2024-01-30 | Vertex Pharmaceuticals Incorporated | Modulators of alpha-1 antitrypsin |
| JP7796115B2 (ja) * | 2020-09-09 | 2026-01-08 | クリネティックス ファーマシューティカルズ，インク． | ソマトスタチン調節因子の製剤 |
| PE20250009A1 (es) * | 2022-05-11 | 2025-01-07 | Lilly Co Eli | Composiciones de comprimidos de glp1 |
-
2023
- 2023-05-10 EP EP23729579.5A patent/EP4522129A1/en active Pending
- 2023-05-10 JP JP2024566219A patent/JP7767651B2/ja active Active
- 2023-05-10 AU AU2023269995A patent/AU2023269995A1/en active Pending
- 2023-05-10 CA CA3253043A patent/CA3253043A1/en active Pending
- 2023-05-10 US US18/864,210 patent/US20250302809A1/en active Pending
- 2023-05-10 PE PE2025002371A patent/PE20260136A1/es unknown
- 2023-05-10 WO PCT/US2023/021637 patent/WO2023220109A1/en not_active Ceased
- 2023-05-10 KR KR1020247040462A patent/KR20250002778A/ko active Pending
- 2023-05-10 PE PE2024002463A patent/PE20251285A1/es unknown
- 2023-05-10 IL IL316629A patent/IL316629A/en unknown
- 2023-05-10 CN CN202380039380.7A patent/CN119173255A/zh active Pending
- 2023-05-11 TW TW113144409A patent/TW202508581A/zh unknown
- 2023-05-11 AR ARP230101165A patent/AR129296A1/es unknown
- 2023-05-11 TW TW112117510A patent/TWI867526B/zh active
-
2024
- 2024-11-05 JO JOJO/P/2024/0245A patent/JOP20240245A1/ar unknown
- 2024-11-06 CL CL2024003392A patent/CL2024003392A1/es unknown
- 2024-11-08 MX MX2024013839A patent/MX2024013839A/es unknown
- 2024-11-08 CO CONC2024/0015285A patent/CO2024015285A2/es unknown
- 2024-11-11 DO DO2024000232A patent/DOP2024000232A/es unknown
-
2025
- 2025-10-29 JP JP2025182180A patent/JP2026021422A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TWI867526B (zh) | 2024-12-21 |
| JOP20240245A1 (ar) | 2024-11-05 |
| TW202508581A (zh) | 2025-03-01 |
| PE20251285A1 (es) | 2025-05-14 |
| IL316629A (en) | 2024-12-01 |
| WO2023220109A1 (en) | 2023-11-16 |
| MX2024013839A (es) | 2024-12-06 |
| CA3253043A1 (en) | 2023-11-16 |
| JP2026021422A (ja) | 2026-02-10 |
| CL2024003392A1 (es) | 2025-03-14 |
| AR129296A1 (es) | 2024-08-07 |
| TW202410894A (zh) | 2024-03-16 |
| CN119173255A (zh) | 2024-12-20 |
| AU2023269995A1 (en) | 2024-11-14 |
| US20250302809A1 (en) | 2025-10-02 |
| DOP2024000232A (es) | 2024-12-30 |
| JP7767651B2 (ja) | 2025-11-11 |
| EP4522129A1 (en) | 2025-03-19 |
| KR20250002778A (ko) | 2025-01-07 |
| JP2025515706A (ja) | 2025-05-20 |
| CO2024015285A2 (es) | 2024-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20251285A1 (es) | Composiciones farmaceuticas de glp1 | |
| US8318746B2 (en) | Nitrogen-containing five-membered heterocyclic compound | |
| US20250115606A1 (en) | Heterocyclic glp-1 agonists | |
| JP4854511B2 (ja) | 糖尿病治療剤 | |
| US20230331732A1 (en) | Heterocyclic glp-1 agonists | |
| US7635713B2 (en) | Pyrrolidine derivatives as prostaglandin modulators | |
| JP2007284350A (ja) | 糖尿病治療剤 | |
| KR20140010031A (ko) | 대사 장애의 치료를 위한 ｂａｃｅ-2 억제제 | |
| US8759334B2 (en) | Compounds useful for the treatment of metabolic and inflammatory diseases | |
| BR112016016224B1 (pt) | Compostos inibidores de dipeptidil peptidase, uso de um composto e combinação | |
| US11104690B2 (en) | Indazole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 | |
| PE20250009A1 (es) | Composiciones de comprimidos de glp1 | |
| US11691968B2 (en) | Compound having KDM5 inhibitory activity and pharmaceutical use thereof | |
| MX2013015078A (es) | Derivados de 1,6- diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas. | |
| HUE031441T2 (hu) | 6-benzilfenil-2-kéntetrahidropirán-3,4,5-triolszármazékokat tartalmazó kombinációk mint nátrium-glükóz ko-transzporter 1 és 2 inhibitorai diabéteszes páciensekben való alkalmazásra | |
| JP2021523910A (ja) | 置換されたジヒドロピラゾロピラジンカルボキサミド誘導体 | |
| US20200000816A1 (en) | Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof | |
| WO2009099172A1 (ja) | 医薬 | |
| KR20170003666A (ko) | 카르복스아미드 유도체 | |
| WO2025189141A1 (en) | Methods for treating obesity and increasing weight loss | |
| US10494364B2 (en) | Cathepsin K inhibitors and application thereof | |
| JP2023545741A (ja) | 新規なジアシルグリセリドｏ－アシルトランスフェラーゼ２阻害剤としてのベンゾイミダゾロン誘導体の製造 | |
| AU758983B2 (en) | Use of a COX-2 inhibitor and a NK-1 receptor antagonist for treating inflammation |